Clene Inc (CLNN) Peer Comparison

$3.91

$-0.17 (-4.17%)

As on 05-Oct-2026 16:02EDT

Market cap

$58 Mln

Revenue (TTM)

$0 Mln

P/E Ratio

--

P/B Ratio

7.8

Div. Yield

0 %

Edit

	Clene Inc (CLNN)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Halozyme Therapeutics (HALO)
Market cap ($ Mln)	58	16,732	14,995	14,468	12,469
Revenue ($ Mln)	0	2,782	1,054	2,436	1,664
Net Profit ($ Mln)	-39.52	491.50	755.85	860.62	413.60
Net Margin (%)	-20,059.90	17.67	71.69	35.33	24.86
RoE (%)	--	110.09	--	42.98	430.03
Price to Earnings	--	35.22	17.89	18.36	31.39
Price-To-Book	7.83	39.70	8.91	7.82	88.91

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement ($ Mln)

	Clene Inc (CLNN)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Halozyme Therapeutics (HALO)
Operating Revenue	0.20	2,782.29	1,054.37	2,435.92	1,663.74
Cost of Revenue	0.41	1,982.07	103.47	85.67	363.07
Gross Profit	0.16	760.62	588.53	2,236.43	1,091.18
Operating Expenses	20.08	216.81	841.45	1,378.74	356.18
Operating Profit (EBIT)	-20.30	583.40	109.45	971.51	944.49
Other Income	0.00	0.00	0.00	0.00	0.00
Profit before Tax	-39.52	598.92	101.11	1,035.47	583.34
Provision for Tax	0.00	107.42	-654.74	174.84	169.74
Profit after Tax (Net Income)	-39.52	491.50	755.85	860.62	413.60
Minority Interest	0.00	0.00	0.00	0.00	0.00
Consolidated Profit	0.00	0.00	0.00	0.00	0.00

Liabilities ($ Mln)

	Clene Inc (CLNN)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Halozyme Therapeutics (HALO)
Shareholder's Funds	-24.78	433.86	1,435.90	1,843.76	143.54
Minority Interest	0.00	0.00	0.00	0.00	0.00
Non-Current Liabilities	42.97	187.89	384.48	288.55	2,089.43
Current Liabilities	4.85	1,435.43	464.70	361.93	344.44
Total Liabilities	18.13	1,975.47	1,302.02	2,844.42	2,525.32

Assets ($ Mln)

	Clene Inc (CLNN)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Halozyme Therapeutics (HALO)
Non-Current Assets	8.13	1,006.90	895.24	1,243.41	1,644.38
Current Assets	14.91	1,050.29	1,389.84	1,250.82	933.02
Total Assets	18.13	1,975.47	1,302.02	2,844.42	2,525.32
Total Debt*	22.34	120.10	449.89	165.93	2,146.65
Net Current Assets	10.06	-385.14	925.52	888.90	588.59

Cashflow ($ Mln)

	Clene Inc (CLNN)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Halozyme Therapeutics (HALO)
Cash From Operating Activities	-18.55	713.22	51.77	884.27	651.56
Cash Flow from Investing Activities	-0.04	-31.14	-8.15	350.44	-545.81
Cash from Financing Activities	11.52	-860.39	34.89	-969.59	-85.17
Net Cash Inflow / Outflow	--	--	--	--	--

Ratios

Profitability Ratios

	Clene Inc (CLNN)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Halozyme Therapeutics (HALO)
ROCE (%)	-325.80	53.56	-30.01	32.82	15.61
ROE (%)	197.91	110.09	163.18	42.98	430.03
ROA (%)	-137.23	15.64	31.68	29.32	16.19
EBIT Margin (%)	-14,850.25	21.13	5.73	41.23	36.28
Net Margin (%)	-20,059.90	17.67	71.69	35.33	24.86
Cash Profit Margin (%)	-0.01	0.00	0.00	0.00	0.00

Growth Ratios

	Clene Inc (CLNN)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Halozyme Therapeutics (HALO)
Revenue Growth (%)	-31.12	24.67	114.85	9.23	41.15
EBIT Growth (%)	-8.84	18.70	136.39	27.56	-14.99
Net Profit Growth (%)	-33.03	17.50	378.76	42.89	-25.78
EPS Growth (%)	11.47	26.84	353.27	50.42	-23.48
Book Value Growth (%)	-122.88	164.02	816.12	-0.70	-55.81

Valuation Ratios

	Clene Inc (CLNN)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Halozyme Therapeutics (HALO)
Price / Earnings	-2.21	36.06	-59.76	15.79	24.99
Price / Book Value	-3.29	35.44	-80.42	5.72	162.23
Dividend Yield (%)	--	--	--	--	--
EV/EBITDA	-3.38	28.08	-121.54	12.44	17.31
Market Cap ($ Cr)	--	--	--	--	--

Solvency Ratios

	Clene Inc (CLNN)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Halozyme Therapeutics (HALO)
Debt to Equity	-0.74	0.00	0.27	0.00	13.50
Short term debt to equity ratio	-0.05	0.00	0.05	0.00	1.46
Current Ratio	3.07	0.73	2.99	3.46	2.71
Quick Ratio	3.07	0.73	2.32	3.38	2.31
Interest Coverage	-12.72	--	1.62	--	29.73

Operating Efficiency Ratios

	Clene Inc (CLNN)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Halozyme Therapeutics (HALO)
Debtors to sales (%)	600.51	15.88	21.25	13.74	27.40
Asset Turnover	0.01	0.89	0.44	0.83	0.65
Receivable days	895.78	50.42	85.52	43.48	98.04
Inventory Days	445.94	--	1,056.70	96.17	190.34
Payable days	9,054.80	6.26	331.01	147.97	18.62
Cash Conversion Cycle	-7,713.08	--	811.21	-8.32	269.75

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly